Table 2 Adverse events (>10% of patients in any group) from a phase 1 study of CAD106 in patients with mild-to-moderate Alzheimer’s disease during the 52-week study period
Cohort 1 | Cohort 2 | |||
|---|---|---|---|---|
Event | CAD106 50 μg (n = 24) | Placebo (n = 7) | CAD106 150 μg (n = 22) | Placebo (n = 5) |
Any serious adverse event | 4 (17) | 1 (14) | 4 (18) | 0 |
Any adverse events | 23 (96) | 6 (86) | 22 (100) | 5 (100) |
Injection site erythema | 1 (4) | 1 (14) | 14 (64) | 0 |
Nasopharyngitis | 10 (42) | 2 (29) | 3 (14) | 0 |
Fatigue | 7 (29) | 0 | 4 (18) | 1 (20) |
Nausea | 4 (17) | 2 (29) | 3 (14) | 0 |
Chills | 1 (4) | 0 | 6 (27) | 0 |
Headache | 5 (21) | 0 | 4 (18) | 1 (20) |
Diarrhea | 3 (13) | 1 (14) | 0 | 1 (20) |
Vomiting | 2 (8) | 1 (14) | 3 (14) | 1 (20) |
Fever | 1 (4) | 0 | 4 (18) | 0 |
Injection site pain | 0 | 0 | 4 (18) | 0 |
Myalgia | 4 (17) | 0 | 0 | 0 |
Fall | 3 (13) | 1 (14) | 1 (5) | 0 |
Back pain | 3 (13) | 0 | 3 (14) | 0 |
Rhinitis | 3 (13) | 0 | 0 | 0 |